In January 2025, Clinical Gastroenterology and Hepatology published a narrative review titled “Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma.”
With MASLD (Metabolic Dysfunction-associated Steatotic Liver Disease) emerging as a leading cause of hepatocellular carcinoma (HCC), this review explores strategies to mitigate HCC risk in at-risk populations.
Key Insights:
Lifestyle Interventions: Healthy diets rich in vegetables, whole grains, fish, poultry, and olive oil—alongside regular physical activity can significantly lower HCC risk.
Pharmacologic Strategies: While not yet guideline-recommended solely for HCC prevention, drugs like metformin, PPAR activators, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, aspirin, and statins show promising potential.
Link with Type 2 Diabetes: Proper anti-diabetic therapy selection in individuals with liver disease and diabetes may also reduce HCC incidence.
This review highlights the urgent need for more data to establish definitive risk-benefit ratios for pharmacological chemoprevention.
Read the full article: https://lnkd.in/gUxs_aX2
